Clinical Pharmacokinetic Studies of Enzalutamide
Jacqueline A Gibbons, Taoufik Ouatas, Walter Krauwinkel, Yoshiaki Ohtsu, Jan-Stefan van der Walt, Vanessa Beddo, Michiel de Vries, Joyce Mordenti, Jacqueline A Gibbons, Taoufik Ouatas, Walter Krauwinkel, Yoshiaki Ohtsu, Jan-Stefan van der Walt, Vanessa Beddo, Michiel de Vries, Joyce Mordenti
Abstract
Background and objectives: Oral enzalutamide (160 mg once daily) is approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This article describes the pharmacokinetics of enzalutamide and its active metabolite N-desmethyl enzalutamide.
Methods: Results are reported from five clinical studies.
Results: In a dose-escalation study (n = 140), enzalutamide half-life was 5.8 days, steady state was achieved by day 28, accumulation was 8.3-fold, exposure was approximately dose proportional from 30-360 mg/day, and intersubject variability was ≤30 %. In a mass balance study (n = 6), enzalutamide was primarily eliminated by hepatic metabolism. Renal excretion was an insignificant elimination pathway for enzalutamide and N-desmethyl enzalutamide. In a food-effect study (n = 60), food did not have a meaningful effect on area under the plasma concentration-time curve (AUC) of enzalutamide or N-desmethyl enzalutamide, and in an hepatic impairment study, AUC of the sum of enzalutamide plus N-desmethyl enzalutamide was similar in men with mild (n = 6) or moderate (n = 8) impairment (Child-Pugh Class A and B) versus men with normal hepatic function (n = 14). In a phase III trial, an exposure-response analysis of steady-state predose (trough) concentrations (C trough) versus overall survival (n = 1103) showed that active treatment C trough quartiles for 160 mg/day were uniformly beneficial relative to placebo, and no threshold of C trough was associated with a statistically significant better response.
Conclusions: Enzalutamide has predictable pharmacokinetics, with low intersubject variability. Similar efficacy was observed in patients across the concentration/exposure range associated with a fixed oral dose of enzalutamide 160 mg/day.
Trial registration: ClinicalTrials.gov NCT00510718 NCT00974311 NCT01901133 NCT01911715.
Figures
References
- Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–790. doi: 10.1126/science.1168175.
- Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, AFFIRM Investigators et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–1197. doi: 10.1056/NEJMoa1207506.
- Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate before chemotherapy. N Engl J Med. 2014;371(5):424–433. doi: 10.1056/NEJMoa1405095.
- US Department of Health and Human Services. Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000. Available at: . Accessed 13 Feb 2015.
- Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, et al. Prostate Cancer Foundation/Department of Defense Prostate Cancer Clinical Trials Consortium. Antitumour activity of enzalutamide in castration-resistant prostate cancer: a phase 1-2 study. Lancet. 2010;24;375(9724):1437–46.
- US Department of Health and Human Services. Bioanalytical method validation. 2001. Available at: . Accessed 13 Feb 2015.
- Bennett D, Gibbons JA, Mol R, Ohtsu Y, Williard C. Validation of a method for quantifying enzalutamide and its major metabolites in human plasma by LC–MS/MS. Bioanalysis. 2014;6(6):737–744. doi: 10.4155/bio.13.325.
- US Department of Health and Human Services. Food-effect bioavailability and fed bioequivalence studies. 2003. Available at: . Accessed 13 Feb 2015.
- US Department of Health and Human Services. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. 2005. Available at: . Accessed 13 Feb 2015.
- Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res. 1993;10(7):1093–1095. doi: 10.1023/A:1018943613122.
Source: PubMed